SCHEMBL1663392

SCHEMBL1663392

CCOC(=O)CC(=O)c1c(F)cccc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
TSHR P16473 1/20 0.49
NLRP3 Q96P20 1/20 0.48
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
KRAS P01116 1/20 0.43
RAB9A P51151 1/20 0.42
KAT6A Q92794 1/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12953136 0.90 ALDH1A1 (0.56) ALDH1A1KMT2AKDM4EMEN1TSHR
SCHEMBL1931504 0.88 NLRP3 (0.55) ALDH1A1KMT2AKDM4EMEN1NLRP3
SCHEMBL9496933 0.85 POLB (0.49) ALDH1A1KMT2AKDM4EMEN1TSHR
SCHEMBL28680615 0.84 CA12 (0.54) ALDH1A1KMT2AKDM4EMEN1TSHR
SCHEMBL30822598 0.82 CA12 (0.54) ALDH1A1KMT2AKDM4ETSHRCA12
SCHEMBL15462888 0.82 CA9 (0.52) KMT2ATSHRCA12CA1CA2
SCHEMBL25204360 0.81 NLRP3 (0.49) ALDH1A1KMT2AKDM4EMEN1NLRP3
SCHEMBL11581780 0.79 KMT2A (0.50) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL25045665 0.79 TSHR (0.48) KMT2AMEN1TSHRNLRP3CA12
SCHEMBL16915385 0.78 KMT2A (0.49) KMT2AMEN1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2490692-B1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2016-11-16 EP disclosed
US-8895580-B2 Quinolinone-pyrazolone M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2014-11-25 US disclosed
EP-2490692-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2012-08-29 EP disclosed
US-20120196845-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2012-08-02 US disclosed
WO-2011049731-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196845-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, OPRL1, CHRNA5 ALDH1A1 2640/4885KMT2A 1958/4885KDM4E 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.